NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 202)
Posted On: 04/27/2022 4:41:11 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Early Access Program for Use of Its Revolutionary UST(TM) Platform
Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty testing services to the worldwide biotechnology and other industries. The company today announced the initiation of an Early Access Program (effective July 1, 2022) for the use of its revolutionary Ultra Shear Technology(TM) (“UST(TM)”) platform for the processing of oil-based active ingredients into highly stable, water-soluble, long-term stable nanoemulsions. “We have announced our plans to have commercial toll-production UST-processing capacity operational on the East and West coasts of the USA by Q4 2022,” said John B. Hollister, director of sales and marketing at PBI. “Since announcing this, we have worked closely with a number of companies on formulating some of their products. As a result, the demand to serve initial contracts for pilot-scale production of nanoemulsions in nutraceuticals, cosmetics, health and beauty care, and agrochemical markets has become particularly intense and is growing. We anticipate the announcement of at least two significant relationships and contracts within these sectors during Q2 2022, for which early small-batch production capacity can be pivotal to accelerating the commercialization phase to follow.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty testing services to the worldwide biotechnology and other industries. The company today announced the initiation of an Early Access Program (effective July 1, 2022) for the use of its revolutionary Ultra Shear Technology(TM) (“UST(TM)”) platform for the processing of oil-based active ingredients into highly stable, water-soluble, long-term stable nanoemulsions. “We have announced our plans to have commercial toll-production UST-processing capacity operational on the East and West coasts of the USA by Q4 2022,” said John B. Hollister, director of sales and marketing at PBI. “Since announcing this, we have worked closely with a number of companies on formulating some of their products. As a result, the demand to serve initial contracts for pilot-scale production of nanoemulsions in nutraceuticals, cosmetics, health and beauty care, and agrochemical markets has become particularly intense and is growing. We anticipate the announcement of at least two significant relationships and contracts within these sectors during Q2 2022, for which early small-batch production capacity can be pivotal to accelerating the commercialization phase to follow.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼